Brief: Sangamo Therapeutics, Chroma Medicine Announce Agreement To Develop Zinc Finger Proteins For Epigenetic Editing
20/07/2023 13:22
July 20 (Reuters) - Sangamo Therapeutics Inc SGMO.O :
* SANGAMO THERAPEUTICS AND CHROMA MEDICINE ANNOUNCE OPTION
AND
LICENSE AGREEMENT TO EVALUATE AND DEVELOP ZINC FINGER PROTEINS
FOR EPIGENETIC EDITING
* SANGAMO THERAPEUTICS - CHROMA TO LEAD, FUND ALL RESEARCH,
DEVELOPMENT, MANUFACTURE, COMMERCIALIZATION OF PRODUCTS
INCORPORATING LICENSED SANGAMO ZFPS
* SANGAMO THERAPEUTICS - IF CHROMA EXERCISES OPTION FOR ANY
OR ALL
TARGETS, CO WOULD BE ELIGIBLE TO RECEIVE OPTION EXERCISE PAYMENT
Source text for Eikon: ID:nBw7gjwDra
Further company coverage: SGMO.O
((Reuters.Briefs@thomsonreuters.com;))